Vanhoutte Cardiovascular Pharmacology: Endothelial Control

1. Auflage 2010
ISBN: 978-0-12-385062-1
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: 6 - ePub Watermark

E-Book, Englisch, Band Volume 60, 336 Seiten

Reihe: Advances in Pharmacology

Cardiovascular disease remains a major cause of death and disability in developed countries and, increasingly so, in the developing world. Presented in this volume of Advances in Pharmacology are some of the most promising possibilities for treating large numbers of individuals afflicted with these conditions. - Contains up-to-date reviews of the most important emerging cardiovascular therapies written by world leaders in the field

Autoren/Hrsg.

Vanhoutte, Paul

Inhaltsverzeichnis

1;Front Cover;1
2;Cardiovascular Pharmacology: Endothelial Control;4
3;Copyright Page;5
4;Contents;6
5;Contributors;10
6;Foreword;14
7;Chapter 1: The Cardiovascular Physiology and Pharmacology of Endothelin-1;16
7.1;I. Introduction;17
7.2;II. Cardiovascular Physiology of ET-1;17
7.3;III. Conclusion;30
7.4;Acknowledgments;30
7.5;References;31
8;Chapter 2: Vascular Pharmacology of Epoxyeicosatrienoic Acids;42
8.1;I. Introduction;43
8.2;II. Biochemistry;43
8.3;III. EETs and Vascular Tone;44
8.4;IV. EETs and Inflammation;54
8.5;V. EETs and Angiogenesis;58
8.6;VI. Conclusion;62
8.7;Acknowledgment;64
8.8;References;65
9;Chapter 3: Prostaglandins in Action: Indispensable Roles of Cyclooxygenase-1 and -2 in Endothelium-Dependent Contractions;76
9.1;I. Introduction;77
9.2;II. COX Isozymes;78
9.3;III. COX-1 and COX-2 in Patho/Physiological States;80
9.4;IV. Controversies over COX-2 Inhibitors and Cardiovascular Events;89
9.5;V. Conclusion;91
9.6;Acknowledgments;92
9.7;References;92
10;Chapter 4: TP Receptors and Oxidative Stress: Hand in Hand from Endothelial Dysfunction to Atherosclerosis;100
10.1;I. Introduction;101
10.2;II. Arachidonic Acid Derivatives and Oxidative Stress;103
10.3;III. Vascular Function;104
10.4;IV. Vascular Inflammation;110
10.5;V. Atherosclerosis;111
10.6;VI. Implications for Clinical Usefulness of TP Antagonists;115
10.7;Acknowledgments;116
10.8;References;117
11;Chapter 5: Regulation of Endothelial Cell Tetrahydrobiopterin: Pathophysiological and Therapeutic Implications;122
11.1;I. Introduction;123
11.2;II. Chemistry and Synthesis of Pterins;124
11.3;III. The Role of BH4 in NOS Function—Concept of NOS Uncoupling;129
11.4;IV. NOS Uncoupling in Diseases;130
11.5;V. Structural Characteristics of GTPCH-1 and Posttranslational Modulation;137
11.6;VI. Conclusion;141
11.7;Acknowledgments;141
11.8;References;142
12;Chapter 6: Polyphenol-Induced Endothelium-Dependent Relaxations: Role of NO and EDHF;148
12.1;I. Introduction: The Epidemiological Evidence;149
12.2;II. Polyphenols Induce Endothelium-Dependent Responses In Vitro and Ex Vivo;150
12.3;III. Polyphenols and Endothelial Function In Vivo;176
12.4;IV. Conclusion;178
12.5;References;179
13;Chapter 7: Organic Nitrates and Nitrate Tolerance—State of the Art and Future Developments;192
13.1;I. Introduction;193
13.2;II. The Phenomenon of Nitrate Tolerance;197
13.3;III. Oxidative Stress;202
13.4;IV. Bioactivation of Organic Nitrates;207
13.5;V. Strategies to Overcome Nitrate Tolerance;221
13.6;VI. New Nitrates;225
13.7;VII. Conclusion, Outlook, and Clinical Relevance;226
13.8;Acknowledgments;228
13.9;References;229
14;Chapter 8: Vascular Actions of Adipokines: Molecular Mechanisms and Therapeutic Implications;244
14.1;I. Introduction;245
14.2;II. Cross-Talk Between Adipose Tissue and Blood Vessels;246
14.3;III. Modulation of Vascular Function by Adipokines;247
14.4;IV. Adiponectin and A-FABP as Therapeutic Targets for Vascular Diseases;258
14.5;V. Conclusion;261
14.6;Acknowledgments;261
14.7;References;262
15;Chapter 9: Cardiovascular Effects of Erythropoietin: An Update;272
15.1;I. Introduction;273
15.2;II. Pharmacokinetics of Erythropoietin;274
15.3;III. Signal Transduction by Erythropoietin;276
15.4;IV. Mechanisms of Vascular Protective Effects of Erythropoietin;278
15.5;V. Erythropoietin and Cardioprotection;284
15.6;VI. Erythropoietin and Cerebrovascular Disorders;286
15.7;VII. Erythropoietin and Progenitor Cells;287
15.8;VIII. Conclusion;289
15.9;Acknowledgments;290
15.10;References;291
16;Index;302
17;Contents of Previous Volumes;310